Novo Nordisk Cuts 9,000 Jobs as Obesity Drug Battle Intensifies

Novo Nordisk will cut around 9,000 jobs, or more than 11% of its global workforce, as the Danish drugmaker confronts intensifying competition from Eli Lilly in the multibillion-dollar obesity and diabetes market. 

The restructuring is expected to generate annualized savings of $1.25 billion by 2026, funds the company says will be redirected toward research and development in its growth engines of diabetes and weight loss.

The move shows the shifting dynamics in a market transformed by Novo Nordisk’s Ozempic, first approved in 2017, and the runaway success of its weight-loss counterpart Wegovy. Both drugs helped propel Novo into Europe’s most valuable listed company, but Eli Lilly has since emerged as a formidable rival with Mounjaro, a dual-acting drug targeting obesity and type 2 diabetes. 

The United States, Novo’s largest market, remains the focal point of this contest, with pricing pressures mounting under the Trump administration. Lilly recently adjusted its UK prices upward in an effort to balance revenues across developed markets, signaling that governments and health systems in Europe may face higher costs as US prices come down.

What Does This Mean for Me?

Despite the layoffs, Novo’s shares rose 2.5% in Copenhagen afternoon trading, trimming earlier gains. Investors remain cautious, with analysts noting that the market is waiting to see how quickly reinvestment from cost savings translates into topline growth. The layoffs highlight the reality that even industry leaders must balance expansion with efficiency in a sector where innovation, regulation, and pricing pressures collide.